Natco Pharma Ltd

Natco Pharma Ltd maintains a strong liquidity position with a current ratio of 5.59, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its cash and equivalents of INR 539 million and a negative net cash position after subtracting total debt. The debt-to-equity ratio of 0.04 reflects a conservative capital structure with minimal leverage.

In terms of profitability, Natco Pharma Ltd demonstrates a return on equity (ROE) of 24.79% and a return on assets (ROA) of 21.85%, both of which are strong indicators of efficient asset utilization and profitability. The company's operating income of INR 19.6 billion and net income of INR 18.85 billion highlight its ability to generate substantial earnings from its operations. These metrics are well above the industry median for pharmaceutical companies, suggesting a competitive edge in cost management and pricing power.

Geographically, Natco Pharma Ltd's revenue is concentrated in India, with a significant portion of its sales derived from domestic markets. The company's exposure to international markets is limited, which may pose a risk in the event of domestic economic downturns or regulatory changes. The company's segmental breakdown is not fully disclosed, but its primary focus remains on the pharmaceuticals business.

Looking at growth, Natco Pharma Ltd has shown consistent revenue performance, with a total revenue of INR 44.295 billion in the latest reporting period. The company's capital expenditures of INR 5.116 billion indicate ongoing investment in infrastructure and production capabilities. Analysts have provided a mean price target of INR 916.10, with a median of INR 902.50, suggesting a generally positive outlook on the company's future performance.

The risk assessment for Natco Pharma Ltd indicates a low dilution risk, with a dilution potential of low and no significant dilution events in the near term. The company's liquidity risk is rated as medium, primarily due to its negative net cash position after accounting for total debt. The credit risk is low, given the company's strong equity base and low debt levels.

Recent events and filings have not indicated any major operational or financial disruptions for Natco Pharma Ltd. The company's financial health remains stable, with no significant red flags in its latest disclosures. Analysts have provided a mean recommendation of 3.00, which is a "Hold" rating, with two strong-buy and one buy recommendation, indicating a generally cautious but positive sentiment.